Welcome to our dedicated page for SBTX news (Ticker: SBTX), a resource for investors and traders seeking the latest updates and insights on SBTX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SBTX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SBTX's position in the market.
Silverback Therapeutics (NASDAQ: SBTX), a biopharmaceutical company, has announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Laura Shawver will present a corporate overview on September 13 at 11:00 a.m. ET. The company focuses on developing therapeutics using its proprietary ImmunoTAC technology for treating cancer and other serious diseases by targeting specific disease sites. Silverback is headquartered in Seattle, Washington.
Silverback Therapeutics (SBTX) reported its Q2 2021 financial results, showcasing significant advancements in its clinical pipeline, particularly with SBT6050, which is in a Phase 1/1b trial for treating advanced HER2-expressing tumors. A clinical supply agreement with Regeneron to evaluate SBT6050 in combination with Libtayo has been announced. However, the company posted a net loss of $24.5 million for Q2, a considerable increase from $6.5 million in Q2 2020, driven by rising research expenses and compensation costs. As of June 30, 2021, cash reserves were $359.7 million.
Silverback Therapeutics (Nasdaq: SBTX), a clinical-stage biopharmaceutical firm, announced its participation in the 2021 Wedbush PacGrow Healthcare Conference on August 10-11, 2021. CEO Laura Shawver will join the 'Heavenly (anti)Bodies' panel on August 10 at 1:10 p.m. ET. The company focuses on developing targeted therapeutics for cancer and chronic viral infections using its proprietary ImmunoTAC platform, which aims to enhance treatment effectiveness by directing specific agents to disease sites. For more details, visit silverbacktx.com.
Silverback Therapeutics (Nasdaq: SBTX) announced a clinical supply agreement with Regeneron for Libtayo® (cemiplimab) to evaluate its efficacy in combination with SBT6050, a novel immuno-oncology agent targeting HER2-expressing tumors. The collaboration aims to enhance immune responses in treating solid tumors like non-small cell lung cancer and gastric cancer. Silverback initiated part 3 of its Phase 1/1b study, focusing on dose escalation and tumor-specific cohorts. This partnership marks a pivotal step in advancing Silverback's ImmunoTAC technology platform for developing targeted cancer therapies.
Silverback Therapeutics, Inc. (Nasdaq: SBTX) is set to participate in the Raymond James Human Health Innovation Conference on June 23, 2021, at 3:20 PM ET. CEO Laura Shawver will present a corporate overview, with a live webcast available on the investor relations website. A replay will be accessible for 30 days. Silverback focuses on developing targeted therapeutics for cancer and serious diseases using its ImmunoTAC platform.
Silverback Therapeutics (Nasdaq: SBTX) announced its participation in the Goldman Sachs 42nd Annual Global Healthcare Conference. The event will feature a fireside chat with CEO Laura Shawver, Ph.D., and President Valerie Odegard, Ph.D., scheduled for June 8, 2021, at 3:50 p.m. ET. The live webcast will be accessible on Silverback’s investor relations website, with a replay available for 30 days. Silverback focuses on developing targeted therapeutics for cancer and other diseases using its proprietary ImmunoTAC technology platform.
Silverback Therapeutics (SBTX) reported its Q1 2021 financial results with a net loss of $18.9 million, significantly higher than the $5.3 million loss in Q1 2020. The increase in losses was attributed to heightened research and development expenses, which rose to $12.2 million due to advancing pipeline programs. General and administrative expenses also surged to $6.6 million, driven by increased personnel costs and operational expenses. Despite these losses, cash and cash equivalents total $374.2 million, adequate to support operations for at least 24 months.
Silverback Therapeutics (Nasdaq: SBTX) will present preclinical data on SBT6290 at the AACR 2021 Conference, showcasing its potential to activate myeloid cells in tumors. SBT6290 targets Nectin4, overexpressed in several solid tumors, aiming to enhance immunotherapy efficacy. The data supports its anti-tumor activity and demonstrates the versatility of Silverback's ImmunoTAC platform, with plans for IND submission in Q4 2021. This candidate, along with the lead program SBT6050, focuses on overcoming immunotherapy resistance in difficult-to-treat cancers.
Silverback Therapeutics reported its 2020 financial results and corporate milestones, highlighting a successful IPO that raised $277.7 million. They initiated the Phase 1/1b trial for SBT6050 with observed pharmacological activity and advanced preclinical work on SBT6290 and SBT8230. The company reported a net loss of $32.9 million for 2020, up from $24.0 million in 2019, primarily due to increased R&D initiatives. As of December 31, 2020, cash and equivalents were $386.6 million, sufficient for at least 24 months of operations.
Silverback Therapeutics (Nasdaq: SBTX) has announced the appointment of Dr. Maria Koehler to its Board of Directors. With over 20 years of biopharmaceutical experience, Dr. Koehler has held key roles in clinical development, including Chief Medical Officer at Repare Therapeutics and Bicycle Therapeutics. Her leadership is expected to strengthen Silverback's growth as it advances its lead drug, SBT6050, in clinical development. Dr. Koehler's expertise in oncology will be crucial as Silverback aims to innovate in tissue-targeted immuno-oncology therapies.
